Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.

Green, a former pharmacist and pharma ad copywriter whose resume includes such agencies as Grey Healthcare and KPR (since ...

The FDA has narrowly beaten the European Medicines Agency (EMA) to the most approved drugs with a new active substance in ...

Jefferies analyst Akash Tewari maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report) today and set a price target of ...

The cancer therapeutics market is set to exceed $400 billion. Read why five pharmaceutical companies offer attractive ...

Analyst David Risinger of Leerink Partners reiterated a Buy rating on Bristol-Myers Squibb (BMY – Research Report), retaining the price target ...

Biopharma executives make their predictions for the year ahead, from a bold forecast for the return of the megadeal to a plea ...

Lotte Biologics CEO James Park aims to secure ADC orders at U.S. plant this year Lotte Biologics new leadership seeks to ...

Among the 55 novel drugs that crossed the regulatory finish line last year were notable new mechanisms of action, coming ...

However, large-cap pharmaceutical companies, including Bristol-Myers Squibb, are seen as well-positioned to mitigate these risks. These are recent developments. This article was generated with the ...

The 43rd J.P. Morgan Healthcare Conference in San Francisco will see active participation by Korean pharmaceutical giants and ...